Novel diagnostic biomarkers for prostate cancer

Journal of Cancer

Volumn 1, Issue 1, 2010, Pages 150-177

  Madu, Chikezie O ^a   Lu, Yi ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Diagnostic biomarkers; Prostate cancer

Indexed keywords

APOLIPOPROTEIN A2; BETA CATENIN; BIOLOGICAL MARKER; CAVEOLIN; CHROMOGRANIN A; CYTOKINE; ENDOGLIN; ESTROGEN; GELATINASE B; HUNTINGTIN; INTERLEUKIN 6; KALLIKREIN; KALLIKREIN 2; LEPTIN; NEURON SPECIFIC ENOLASE; PLASMINOGEN ACTIVATOR; PROGASTRIN RELEASING PEPTIDE[31-98]; PROSTASOME; PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UVOMORULIN; VASCULOTROPIN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; DNA DETERMINATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; PATIENT CARE; PATIENT IDENTIFICATION; PROGNOSIS; PROSTATE CANCER; REVIEW; RNA ANALYSIS;

EID: 78650606864     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.1.150     Document Type: Review

References (279)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. [Internet] Prostate Cancer Foundation. Home page of Prostate Cancer Foundation. http://www.prostatecancerfoundation.org.
3. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995, NIH Pub No 99-4543. Bethesda, MD: SEER Program, National Cancer Institute. 1999.
4. [Internet] US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Prostate Cancer Screening: A Decision Guide for African Americans. http://www.ustoo.org/PDFs/CDC_PCa_Screen_Guide_AA.pdf.
5. Atkinson AJ Jr, Colburn WA, DeGruttola VG, DeMets DL, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Biomarkers Definitions Working Group. Clinical Pharmacol & Therapeutics 2001; 69: 89-95.
6. [Internet] Woodcock J. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development. http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4079S2_03_Woodcock.ppt.
7. [Internet] National Cancer Institute. Dictionary of Cancer Terms. http://www.cancer.gov/dictionary/?searchTxt=biomarker.
8. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development: a critical appraisal. Br J Clin Pharmacol 1997; 44: 219-25.
9. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-83.
10. Committee on Developing Biomarker-Based Tools for Cancer Screening Diagnosis and Treatment. Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Washington DC: National Academies Press. 2007.
11. Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Where are we going? Ann Intern Med 1992; 116: 599-601.
12. Sawyers CL. The cancer biomarker problem. Nature 2008; 452: 548-52.
13. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998; 58: 4497-504.
14. Smith RA, Mettlin CJ, Eyre H. Cancer Medicine: Cancer Screening and Early Detection. In: Kufe DW, et al, editors. Cancer Medicine. Hamilton, Canada: BC Decker Inc. 2003.
15. [Internet] Theodorescu D, Krupski T. Prostate Cancer - Biology, Diagnosis, Pathology, Staging, and Natural History. http://www.emedicine.com.
16. Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin 1989; 39: 376-93.
17. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer treatment: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-8.
18. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74.
19. Ohori M, Wheeler TM, Dunn JK, et al. The pathologic features and prognosis of prostate cancers detectable with current diagnostic tests. J Urol 1994; 152: 1714-20.
20. Montie JM, Wood DP, Pontes JE, et al. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989; 63: 381-5.
21. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1732-6.
22. Oh WK, Hurwitz M, D'Amico AV, et al. Neoplasms of the Prostate. In: Kufe DW, et al, editors. Cancer Medicine. Hamilton, Canada: BC Decker Inc. 2003.
23. Yano M, Imamoto T, Suzuki H, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol 2007; 51: 375-80.
24. Fielding LP, Genglio-Presier CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992; 70: 2367-77.
25. Jewett HJ. The present status of radi cal prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975; 2: 105-24.
26. th ed. New York, NY: Springer. 2002: 309-16.
27. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994; 10: 60-72.
28. American Joint Committee on Cancer. Prostate cancer. In: Fleming, ID; Cooper, JS; Henson, DE; Hutter, RVP, editors. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott; 1997; 219-24.
29. Montie JE. Staging of prostate cancer: current TNM classification and future prospects for prognostic factors. Cancer 1995; 75 (7 Suppl): 1814-8.
30. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: The Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsy. J Urol 1994; 152: 1721-9.
31. Mettlin C, Lee F, Drago J, et al. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-58.
32. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
33. Basler JW, Thompson IM. Lest we abandon digital rectal examination as a screening test for prostate cancer. J NCI 1998; 90: 1761-3.
34. Mahon, SM. Screening for prostate cancer: informing men about their options. Clinical Journal of Oncology Nursing 2005; 9: 5.
35. Yedema CA, Kenemans P, Voorhorst F, et al. CA 125 half-life in ovarian cancer. A multivariate survival analysis. Br J Cancer 1993; 67: 1361-7.
36. Jacobsen SJ, Bergstralh EJ, Katusic SK, et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 1998; 52: 173-9.
37. Friedman GD, Hiatt Ram, Quesenberry CP, et al. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991; 337: 1526-9.
38. Richert-Boe KE, Humphrey LL, Glass AG, et al. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen 1998; 5: 99-103.
39. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 917-29.
40. Hara M, Koyanagi Y, Inoue T, et al. Some physico-chemical characteristics of "-seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi 1971; 25: 322-4.
41. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 1973; 24: 134-44.
42. Sensabaugh GF, Golden VL. Phenotype dependence in the inhibition of red cell acid phosphatase (ACP) by folates. Am J Hum Genet 1978; 30: 553-60.
43. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63.
44. Stamey TA, Yang N, Hay AR, et al. E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
45. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen. J Urol 1994; 152: 1358-68.
46. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen. A decade of discovery-what we have learned and where we are going. J Urol 1999; 162: 293-306.
47. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int 2008; 101: 5-10.
48. Chu MT. Prostate-specific antigen and early detection of prostate cancer. Tumor Biol 1997; 18: 123-34.
49. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24: 275-82.
50. Stenman UH, Leinonen J, Zhang WM. Standardization of PSA determinations. Scand J Clin Lab Invest (Suppl) 1995; 221: 45-51.
51. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.
52. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995; 274: 1277-81.
53. Presti JC Jr, Hovey R, Bhargava V, et al. Prospective evaluation of prostate specific antigen and prostate specific anti gen density in the detection of carcinoma of the prostate: ethnic variations. J Urol 1997; 157: 907-11.
54. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335: 304-10.
55. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4.
56. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-52.
57. Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer. Association with metastatic levels of prostate specific antigen. J Urol 1993; 149:510-5.
58. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54.
59. Balducci L, Pow-Sang J, Friedland J, et al. Prostate cancer. Clin Geriatr Med 1997; 13: 283-306.
60. [Internet] Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. http://seer.cancer.gov/csr/1975_2005/.
61. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: Interpreting trends in prostate cancer-Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017.
62. Feuer EJ, Etzioni R, Cronin KA, et al. A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004; 13: 421.
63. Polednak AP. Estimating the prevalence of cancer in the United States. Cancer 1997; 80: 136-41.
64. Kirby R, Kirby M, Fitzpatrick J, et al. Shared Care for Prostate Disease. Oxford: ISIS Medical Media, 1994.
65. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annual Review of Public Health 2001; 22: 91-113.
66. Hakama M, Auvinen A. Cancer screening. In: Heggenhougen, Kl; Quah, SR, editors. International Encyclopedia of Public Health. San Diego, CA: Academic Press, 2008: 464-80.
67. Andriole GL, Grubb RL III, Buys SS, et al. The PLCO Project Team. Mortality results from a randomized Ppostate-cancer screening trial. NEJM 2009; 360: 1310-9.
68. Aus G, Ahlgren G, Bergdahl S, et al. Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis. Br J Urol 1996; 77: 851-5.
69. Rietbergen JB, Kruger AE, Kranse R, et al. Complications of transrectal ultrasound-gui ded systemati c sextant bi opsi es of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997; 49:875-80.
70. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J NCI 1999; 91:1950-6.
71. Alibhai SMH, Leach M, Tomlinson G, et al. 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J NCI 2005; 97: 1525-32.
72. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J NCI 2004; 96: 1358-67.
73. Lim AJ, Brandon AH, Fiedler J, et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995; 154:1420-5.
74. Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 2517-26.
75. Fowler FJ Jr, McNaughton Collins M; Walker Corkery E, et al. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002; 95: 287-95.
76. Tsai HK, D'Amico AV, Sadetsky N, et al. Chen, MH; Carroll, PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. JNCI 2007; 99: 1516-24.
77. Punnen S, Nam RK. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA era. Surg Oncol 2009; 18: 192-9.
78. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146-52.
79. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate carcinoma with prostate specific antigen. J Urol 1992; 147:841-5.
80. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846-51.
81. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90.
82. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin 2000; 50: 7-33.
83. Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52.
84. Moul JW. Treatment options for prostate cancer. Part I. Staged, grade, PSA, and changes in the 1990's. Am J Managed Care 1998; 4: 1031-6.
85. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167-70.
86. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80: 1835-44.
87. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1679-84.
88. Tarone RE, Chu KC, Brawley OW. Implications of stage specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167-70.
89. Smart CR. The results of prostate carcinoma screening in the US as reflected in the Surveillance, Epidemiology, and End Results program. Cancer 1997; 80: 1835-44.
90. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1679-84.
91. Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 1995; 28: 221-41.
92. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer- part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J NCI 1999; 91: 1025-32.
93. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064-8.
94. Stephenson RA. Population-based prostate cancer trends in the PSA era: data from the Surveillance, Epidemiology, and End Results Program. Monographs in Urology 1998;: 3-19.
95. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer- part III: quantifying the link between population prostate specific antigen testing and recent declines in prostate cancer mortality. J NCI 1999; 91: 1033-9.
96. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer. Part 1. Prior probability and effectiveness of tests. Ann Intern Med. 1997; 126(5): 394-406.
97. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004; 10: 3943-53.
98. Hartwell L, Mankoff D, Paulovich A, et al. Cancer biomarkers: a systems approach. Nature Biotechnology 2006; 24: 905-8.
99. Cox TM. Biomarkers in lysosomal storage diseases. Fabry disease: Perspectives from 5 years of FOS. In: Mehta, A; Beck, M; Sunder-Plassmann, G, editors. Oxford (UK): Oxford Pharma-Genesis Ltd.; 2006.
100. [Internet] Woodcock J. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development. http://www.fda.gov/ohrms/dockets/ac/04/slides/20044079S2_03_Woodcock.ppt>.
101. Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005; 35: 259-67.
102. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054-61.
103. Barker PE. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann NY Acad Sci 2003; 983: 142-50.
104. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer 2005; 5: 845-56.
105. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995; 154: 407-13.
106. Makarov DV, Loeb S, Getzenberg RH, et al. Biomarkers for prostate cancer. Ann Rev Medicine 2009; 60: 139-51.
107. Taskén KA, Angelsen A, Svindland A, et al. Markers for diagnosis, prediction and prognosis of prostate cancer. Tidsskr Nor Laegeforen 2005; 125: 3279-82.
108. Gutman AB, Gutman EB. An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938; 17: 473-8.
109. Veeramani S, Yuan TC, Chen SJ, et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 2005; 12: 805-22.
110. Gutman AB, Gutman EB, Robinson JN. Determination of serum 'acid' phosphatase activity in differentiating skeletal metastases secondary to prostatic carcinoma from Paget's disease of bone. Am J Cancer 1940; 38: 103-8.
111. Doe RP, Seal US. Acid phosphatase in urology. Surg Clin North Am 1965; 45: 1455-66.
112. Whitesel JA, Donohue RE, Mani JH, et al. Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol 1984; 131: 70-7.
113. Johnson DE, Prout GR, Scott WW, et al. Clinical significance of serum acid phosphatase levels inadvanced prostatic carcinoma. Urology 1976; 8: 123-6.
114. Bishop MC, Hardy JG, Taylor MC, et al. Bone imaging and serum phosphatases in prostatic carcinoma. Br J Urol 1985; 57: 317-24.
115. Lilja H, Haese A, Björk T, et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999; 162: 2029-34.
116. Sokoll LJ, Partin AW, Mikolajczyk SD, et al. ProPSA in relation to free PSA gives the best performance in detecting cancer in the 2.5-4.0 ng/mL total PSA range. J Urol 2002; 167: 286.
117. Ercole CJ, Lange PH, Mathisen M, et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138: 1181-4.
118. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.
119. Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am 1993; 20: 589-95.
120. Han M, Piantadosi S, Zahurak ML, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 2001; 57: 707-11.
121. Oberaigner W, Horninger W. Klocker H. Schönitzer D; Stühlinger, W; Bartsch, G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 2006; 164: 376-84.
122. Antenor JA, Roehl KA, Eggener SE, et al. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005; 66: 156-60.
123. Nadler RB, Loeb S, Roehl KA, et al. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 2005; 174: 2154-7.
124. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
125. Han M, Partin AW, Chan DY, et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004; 171: 23-36.
126. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65.
127. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
128. Kuefer R, Varambally S, Zhou M, et al. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 2002; 161: 841-8.
129. Zha S, Ferdinandusse S, Denis S, et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 2003; 63: 7365-76.
130. Jiang Z, Wu CL, Woda BA, et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology 2004; 45: 218-25.
131. Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662-70.
132. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002; 26: 1169-74.
133. Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220-6.
134. Rogers CG, Ya G, Zha S, et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase protein. J Urol 2004; 172: 1501-3.
135. Sreekumar A, Laxman B, Rhodes DR, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J NCI 2004; 96: 834-43.
136. Cardillo MR, Gentile V, Ceccariello A, et al. Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer? BMC Cancer 2005; 5: 111.
137. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
138. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 11733-7.
139. Harden SV, Guo Z, Epstein JI, et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003; 169: 1138-42.
140. Jerónimo C, Varzim G, Henrique R, et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2002; 11: 445-50.
141. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J NCI 2001; 93: 1747-52.
142. Chu DC, Chuang CK, Fu JB, et al. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol. 2002; 167: 1854-8.
143. Brooks JD, Weinstein M, Lin X, et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomark Prev 1998; 7: 531-6.
144. Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001; 7: 2727-30.
145. Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159: 1815-26.
146. Bastian PJ, Ellinger J, Schmidt D, et al. GSTP1 hypermethyl ati on as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age? Eur J Med Res. 2004; 9: 523-7.
147. Gonzalgo ML, Pavlovich CP, Lee SM, et al. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003; 9: 2673-7.
148. Gonzalgo ML, Nakayama M, Lee SM, et al. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 2004; 63: 414-8.
149. Simon JP, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J 1989; 262:1-13.
150. Helman LJ, Ahn TG, Levine MA, et al. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem 1988; 263: 11559-63.
151. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12: 109-17.
152. Deftos LJ. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer. Prostate (Suppl) 1998; 8: 23-31.
153. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590-7.
154. Zaky Ahel M, Kovacic K, Kraljic I, et al. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res 2001; 21:1475-9.
155. Ferrero-Pous M, Hersant AM, Pecking A, et al. Serum chromogranin-A in advanced prostate cancer. BJU Int 2001; 88: 790-6.
156. Cabrespine A, Guy L, Gachon F, et al. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006; 175: 1347-52.
157. Sasaki T, Komiya A, Suzuki H, et al. Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 2005; 48: 224-30.
158. Zitella A, Berruti A, Destefanis P, et al. Gruppo Oncologico Urologico Piemontese (GOUP). Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia. Clin Chim Acta 2007; 377: 103-7.
159. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Diseases 2008; 11: 216-29.
160. Isshiki S, Akakura K, Komiya A, et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167: 512-5.
161. Cheville JC, Tindall D, Boelter C, et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002; 95: 1028-36.
162. Fracalanza S, Prayer-Galetti T, Pinto F, et al. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination. Urol Int 2005; 75: 57-61.
163. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology. 1998; 51: 141-5.
164. Riegman PH, Vlietstra RJ, Klaassen P, et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 1989; 247: 123-6.
165. Dawson NA, Vogelzang NJ. Prostate Cancer. New York: Wiley-Liss Inc; 1994.
166. Myrtle JF, Klimley PG, Ivor LP, et al. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. In: Advances in cancer diagnostics. San Diego, CA: Hybritech Inc., 1986; 1-4.
167. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61: 6029-33.
168. Wang TY, Kawaguchi TP. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Ann Clin Lab Sci 1986; 16: 461-6.
169. Beckett ML, Cazares LH, Vlahou A, et al. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res 1999; 5: 4034-40.
170. Murphy GP, Kenny GM, Ragde H, et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998; 51: 89-97.
171. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-40.
172. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19:1288-96.
173. Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004; 171: 1117-21.
174. Hara N, Kasahara T, Kawasaki T, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002; 8: 1794-9.
175. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002; 62: 2546-53.
176. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001; 98: 2658-63.
177. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000; 60: 5522-8.
178. Getzenberg RH, Pienta KJ, Huang EY, et al. Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 1991; 51: 6514-20.
179. Uetsuki H, Tsunemori H, Taoka R, et al. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005; 174: 514-8.
180. Dhir R, Vietmeier B, Arlotti J, et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004; 171: 1419-23.
181. Hansel DE, DeMarzo AM, Platz EA, et al. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 2007; 177: 1736-40.
182. Paul B, Dhir R, Landsittel D, et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005; 65: 4097-100.
183. Epstein JI, Pizov G, Steinberg GD, et al. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. J Urol 1992; 148: 87-91.
184. Partin AW, Steinberg GD, Pitcock RV, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992; 70: 161-8.
185. Babiarz J, Peters JM, Miles B, et al. Crissman, JD. Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma. Anal Quant Cytol Histol 1993; 15: 158-64.
186. Veltri RW, Partin AW, Epstein JE, et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem (Suppl) 1994; 19: 249-58.
187. Carmichael MJ, Veltri RW, Partin AW, et al. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995; 153: 1015-19.
188. Badalament RA, Miller MC, Peller PA, et al. RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996; 156: 1375-80.
189. Bubendorf L, Tapoa C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 949-54.
190. Su SL, Boynton AL, Holmes EH, et al. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction. Semin Surg Oncol 2000; 18: 17-28.
191. Scherr DS, Vaughan EDJ, Wei J, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999; 162: 12-6.
192. Feneley MR, Partin AW. Indicators of pathololgic stage of prostate cancer and their use in clinical practice. Urol Clin North Am 2001; 28: 443-58.
193. Kwiatkowski MK, Recker F, Piironen T et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/ml. Urology 1998; 52: 360-5.
194. Becker C, Noldus J, Diamandis E, et al. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001; 38: 357-99.
195. Haese A, Becker C, Noldus J, et al. Human glandular kallikrein 2. A potential serum marker for predicting the organ-confined versus non-organ-confined growth of prostate cancer. J Urol 2000; 163:1491-7.
196. Chapoval AI, Ni J, Lau JS, et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269-74.
197. Suh WK, Gajewska BU, Okadal H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003; 4: 899-906.
198. Zang X, Allison JP. The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 2007; 13: 5271-9.
199. Luol L, Chapoval AI, Flies DB, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 2004; 173: 5445-50.
200. Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes. J Immunol 2002; 168: 6294-7.
201. Petroff MG, Kharatyan E, Torry DS, et al. The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta. Am J Pathol 2005; 167: 465-73.
202. Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci USA 2008; 105: 10277-8.
203. Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007; 67: 7893-900.
204. Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 2007; 104: 19458-63.
205. Chavin G, Sheinin Y, Crispen PL, et al. RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 2009; 15: 2174-80.
206. Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
207. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 799-800.
208. Couzin J. Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science 2009; 323: 865.
209. Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation and muscul ar dystrophy. Cell Sci 2000; 113: 2103-9.
210. Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998; 273: 5419-22.
211. Tirado OM, Maccarthy CM, Fatima N, et al. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer 2010;126(2):426-36.
212. Liedtke C, Kersting C, Burger H, et al. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007; 5: 110.
213. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 2008; 84: 177-89.
214. Yang G, Addai J, Wheeler TM, et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol 2007; 38: 1688-95.
215. Barresi V, Cerasoli S, Tuccari G. Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology 2008; 28: 472-8.
216. Tahir SA, Yang G, Goltsov AA, et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68: 731-9.
217. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-85.
218. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4: 1873-80.
219. Yang G, Troung LD, Wheeler TM, et al. Caveolin-1 expression in clinically confined human cancer: a novel prognostic marker. Cancer Res 1999; 59: 5719-23.
220. Thompson TC, Tahir SA, Li L, et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 2010; 13: 6-11.
221. Di Vizio D, Morello M, Sotgia F, et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8: 2420-24.
222. Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn 2008; 8: 395-404.
223. Lin KI, Chattopadhyay N, Bai M, et al. Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem Biophys Res Commun 1998; 249: 325-31.
224. Vanaja DK, Grossmann ME, Cheville JC, et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 2009; 27: 264-72.
225. Lallet-Daher H, Roudbaraki M, Bavencoffe A, et al. Intermediate-conductance Ca2+=activated K+ channels (IKcal) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 2009; 28: 1792-806.
226. Liao J, Schneider A, Datta NS, et al. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006; 77: 9065-73.
227. Schwartz GG. Is serum calcium a biomarker of fatal prostate cancer? Future Oncol 2009; 5: 577-80.
228. Vanaja DK, Ballman KV, Morlan BW, et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006; 12: 1128-36.
229. Vanaja DK, Grossmann ME, Cheville JC, et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 2009; 27:264-72.
230. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9.
231. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-98.
232. Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009 Feb; 103: 441-5.
233. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-88.
234. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5.
235. Chun FK, de la Taille A, van Poppel H, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009; 56: 659-68.
236. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179:1804-9.
237. Whitman EJ, Groskopf J, Ali A, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008; 180: 1975-8.
238. Wang R, Chinnaiyan AM, Dunn RL, et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009; 115: 3879-86.
239. Phé V, Rouprêt M, Salomon L, et al. What's new in 2008 in the field of basic and clinical research in prostate cancer? Prog Urol 2009; 19: S29-42.
240. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-5.
241. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15.
242. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-95.
243. Deras IL, Aubin SM, Blasé A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92.
244. Ankerst DP, Groskopf J, Day JR, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 2008; 180: 1303-8.
245. Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol 2008; 10: 175-81.
246. Shappell SB, Fulmer J, Arguello D, et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009; 73:363-8.
247. Ouyang B, Bracken B, Burke B, et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009; 181: 2508-13.
248. Clarke RA, Zhao Z, Guo AY, et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009; 4:e4995.
249. Wilson S, Greer B, Hooper J, et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005; 388: 967-72.
250. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
251. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
252. Mwamukonda K, Chen Y, Ravindranath L, et al. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. Prostate Cancer Prostatic Dis 2010; 13: 47-5.
253. Cai C, Wang H, Xu Y, et al. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009; 69: 6027-32.
254. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the di agnosi s and prognosi s of prostate cancer. Clin Chem 2008; 54: 1951-60.
255. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
256. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15: 4706-11.
257. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-60.
258. Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol 2009; 19: 243-6.
259. Keller S, Sanderson MP, Stoeck A, et al. Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006; 107: 102-8.
260. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
261. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100: 1603-7.
262. Mitchell PJ, Welton J, Staffurth J, Court J, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 2009 Jan 12; 7:4.
263. Jansen FH, Krijgsveld J, van Rijswijk A, et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics 2009; 8: 1192-205.
264. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.
265. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5.
266. Khatami A, Hugosson J, Wang W, et al. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand J Urol Nephrol 2009; 43: 12-8.
267. Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-93.
268. Khor LY, Bae K, Paulus R et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27: 3177-84.
269. Jhavar S, Bartlett J, Kovacs G, et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 2009; 12: 143-7.
270. Wright LM, Yong S, Picken MM, et al. Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol 2009; 2: 34-47.
271. Wei S, Dunn TA, Isaacs WB, et al. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 2008; 68: 1387-95.
272. Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008; 68: 645-9.
273. Kristiansen G, Fritzsche FR, Wassermann K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 2008; 99: 939-48.
274. Chen H, Pong RC, Wang Z, et al. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 2002; 79: 573-81.
275. Chen H, Toyooka S, Gazdar AF, et al. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003; 278:3121-30.
276. Wang Z, Tseng CP, Pong RC, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 2002; 277: 12622-31.
277. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437-44.
278. Chen H, Toyooka S, Gazdar AF, et al. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003; 278: 3121-30.
279. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate put ative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-44.